Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmaceutical products to treat serious neuropsychiatric conditions and focused on improving biodefense through developing potential medical counter-measures. The company’s lead product candidate, Tonmya, or TNX-102 SL, is in phase 3 development as a bedtime treatment for PTSD and is also being developed as a bedtime treatment for agitation in Alzheimer’s patients. Tonmya has undergone a pre-IND (Investigational New Drug) meeting with the FDA, and the company’s TNX-601 (tianeptine oxalate) is in the pre-IND application stage for daytime dosing to treat PTSD. The company’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus. For more information, visit the company’s website at www.tonixpharma.com.
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com